Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
Repeat administration of MDNA11 at the target doses continues ... Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 mg Q6W KEYTRUDA.
M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback